139 related articles for article (PubMed ID: 34083277)
1. Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer
Liu YC; Hsu FT; Chung JG; Weng MC; Ting CY; Tsai CJ; Lan A; Wu JY; Lin CC; Lin SS
Anticancer Res; 2021 Jun; 41(6):2867-2874. PubMed ID: 34083277
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib Inhibits AKT/NF-κB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.
Liu YC; Huang BH; Chung JG; Liu WL; Hsu FT; Lin SS
Anticancer Res; 2021 Jan; 41(1):123-130. PubMed ID: 33419805
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
[TBL] [Abstract][Full Text] [Related]
4. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lung tumor growth by targeting EGFR/VEGFR-Akt/NF-κB pathways with novel theanine derivatives.
Zhang G; Ye X; Ji D; Zhang H; Sun F; Shang C; Zhang Y; Wu E; Wang F; Wu F; Tian H; Liu X; Chen L; Liu K; Wang Y; Liu H; Zhang W; Guan Y; Wang Q; Zhao X; Wan X
Oncotarget; 2014 Sep; 5(18):8528-43. PubMed ID: 25138052
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
Song L; Xiong H; Li J; Liao W; Wang L; Wu J; Li M
Clin Cancer Res; 2011 Apr; 17(7):1839-49. PubMed ID: 21325072
[TBL] [Abstract][Full Text] [Related]
8. Consumption of S-allylcysteine inhibits the growth of human non-small-cell lung carcinoma in a mouse xenograft model.
Tang FY; Chiang EP; Pai MH
J Agric Food Chem; 2010 Oct; 58(20):11156-64. PubMed ID: 20866043
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
10. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
11. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
[TBL] [Abstract][Full Text] [Related]
12. GDC-0349 inhibits non-small cell lung cancer cell growth.
Yang H; Zhao J; Zhao M; Zhao L; Zhou LN; Duan Y; Li G
Cell Death Dis; 2020 Nov; 11(11):951. PubMed ID: 33154352
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
[TBL] [Abstract][Full Text] [Related]
14. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H
Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
16. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
17. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
18. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
